SLE Registry in Pakistan to understand how lupus presents and progresses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a longitudinal, prospective cohort registry to characterize SLE phenotypes, treatments, and outcomes in Pakistani adults. Trained clinicians will collect standardized, validated data from patients diagnosed with SLE, with plans to expand to additional centers nationwide. The study uses existing diagnostic criteria (SLICC 2012 or EULAR/ACR 2019) and observes real-world treatment patterns and disease progression without an active intervention. Data will be analyzed to identify factors influencing disease course and inform practice guidelines locally and regionally.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- All patients presenting with SLE diagnosed by phyician and fulfilling SLICC2012 or EULAR/ACR2019 criteria.

Exclusion Criteria:

\- SLE patient who defers informed consent.

Where it's running

• Fauji Foundation Hospital, Rawalpindi
  Rawalpindi, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Dr. Shahida Perveen, FCPS, Rheumatology
• Email: shahida.perveen@fui.edu.pk
• Phone: 03325235661

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FT819 in Lupus Nephritis: a targeted cell therapy trial for moderate-to-severe LN

  This trial tests whether FT819, a donor-derived CAR T cell therapy, can help people with difficult-to-treat lupus nephritis who have not responded to other medicines.

  Recruiting at 12 sites Phase 2 Fate Therapeutics · Beverly Hills, California and 11 other locations · NCT07570862

• IASO-782 for Systemic Lupus Erythematosus

  A small, early-stage trial tests whether IASO-782 is safe and tolerable for adults with SLE, using a randomized, placebo-controlled design.

  Recruiting at 4 sites Phase 1 Nanjing IASO Biotechnology Co., Ltd. · Hangzhou, Zhejiang and 3 other locations · NCT07483346

• Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases

  This will try a single infusion of off-the-shelf (allogeneic) CAR T-cells that target CD19 and BCMA in adults whose autoimmune disease has relapsed or not responded to other treatments.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07315087

• Umbilical cord blood CAR-T therapy for refractory systemic lupus erythematosus

  This will test an off-the-shelf umbilical cord blood–derived CAR‑T cell therapy targeting CD19 and BCMA to see if it helps adults with treatment‑resistant SLE.

  Recruiting Early Phase 1 Chengdu Ucello Biotechnology Co., Ltd. · Yancheng, Jiangsu and 1 other locations · NCT07274059

• CC312 for relapsed or treatment‑resistant lupus, inflammatory myopathies, and systemic sclerosis

  This early-phase test will try CC312 to see if it is safe and may help adults aged 18–65 with relapsed or treatment‑resistant systemic lupus erythematosus, idiopathic inflammatory myopathies, or systemic sclerosis.

  Recruiting Early Phase 1 CytoCares Inc · Deyang, Sichuan · NCT07193810

• CC312 for adults with moderate to severe lupus

  This Phase 1 trial will test whether CC312 is safe and shows early benefit in adults with moderate to severe lupus.

  Recruiting Phase 1 CytoCares Inc · Chengdu, Sichuan · NCT07177911

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.